Federal · 119th Congress
Protecting Consumer Access to Generic Drugs Act of 2026
Policy areaHealth
The Congressional Research Service has not published a summary of this measure.
Read the text of the bill →Sponsor
Other titles2
To prohibit brand name drug manufacturers from compensating generic drug manufacturers to delay the entry of a generic drug into the market, to prohibit biological product manufacturers from compensating biosimilar and interchangeable product manufacturers to delay entry of biosimilar and interchangeable products, and for other purposes.Official Title as Introduced
Protecting Consumer Access to Generic Drugs Act of 2026Short Title(s) as Introduced
Legislative history3
Oct 22, 2026
HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 22, 2026
HouseReferred to the Committee on Energy and Commerce, and in addition to the Committee on the Judiciary, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned.
Oct 22, 2026
IntroducedIntroduced in House